查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1971041

抗肥胖药物市场－全球产业规模、份额、趋势、机会与预测：按作用机制、药物类型、地区和竞争格局划分，2021-2031年

Anti-Obesity Drugs Market - Global Industry Size, Share, trends, Opportunity, and Forecast, Segmented By Mechanism (Peripherally Acting Drugs, Centrally Acting Drugs), By Drug Type (Prescription Drugs, OTC Drugs), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球抗肥胖药物市场预计将从 2025 年的 32.1 亿美元成长到 2031 年的 80.4 亿美元，复合年增长率为 16.54%。

该领域涵盖旨在透过调节食慾、影响代谢和促进营养吸收等机制来促进体重减轻和维持的药物製剂。受慢性体重相关疾病的增加以及药物疗法在治疗第2型糖尿病等合併症方面日益普及的推动，该市场呈现稳定增长的态势。世界肥胖联盟（WOF）预测，到2030年，全球成年人肥胖人口将达到11.3亿，反映了有效医疗介入的迫切性。

市场概览
预测期 2027-2031
市场规模：2025年 32.1亿美元
市场规模：2031年 80.4亿美元
复合年增长率：2026-2031年 16.54%
成长最快的细分市场 处方药
最大的市场 北美洲

然而，市场扩张的主要障碍在于新疗法的高成本以及许多地区保险报销体系的不完全。这些经济障碍往往使患者无法获得长期治疗方案，从而可能延缓先进体重管理方案的普及，尤其是在低收入者身上。

市场驱动因素

全球肥胖和超重人口的成长是推动市场扩张的主要动力，亟需治疗性介入来减轻公共卫生负担。日益严重的代谢危机刺激了人们对药物解决方案的需求，以应对严重的体重相关併发症，并将医疗保健的重点转向健康管理，以预防危及生命的疾病。根据世界肥胖联盟于2025年3月发布的《2025年世界肥胖地图集》，超重和肥胖每年导致约160万人死于非传染性疾病，凸显了对有效药物治疗的迫切需求。

同时，基于肠促胰素疗法的显着临床疗效和商业性成功正在改变这一领域。这些疗法在调节食慾和代谢功能方面树立了新的治疗标准，生物製药显着的减重效果也证明了药物治疗在体重管理方面的有效性。因此，处方量激增，带动了强劲的收入成长。为了应对这项商业性成功，竞争对手正在加速开发下一代促效剂。根据诺和诺德公司于2025年2月发布的2024财年年度报告，其肥胖症治疗产品的销售额成长了57%，达到651亿丹麦克朗。此外，Fierce Pharma在2024年12月的一篇报导中报道称，该公司将额外投资29亿丹麦克朗，以扩大品管能力。

市场挑战

新型抗肥胖药物价格高昂（通常每年超过数千美元）以及保险政策的限制，大大阻碍了市场的快速扩张。健康保险公司和支付方担心药物广泛使用所带来的经济负担，因此实施了严格的准入机制，例如复杂的预先核准要求和严格的BMI基准值。这种报销环境造成了临床需求与商业性准入之间的巨大差距，实际上将大规模一部分合格医疗条件但无力承担自付费用的患者排除在外，并将药物的使用限制在富裕人群中。

根据管理式医疗药房学院（Managed Care Pharmacy Academy）2025年发布的行业数据，平均而言，只有31%的商业保险用户享有抗肥胖药物的医保，而支付方则将预算大幅增加视为扩大医保覆盖范围的主要障碍。这种有限的健保覆盖迫使绝大多数潜在患者自行承担高昂的费用，直接导致销售量下降，并阻碍了市场充分发挥其收入潜力。这些经济壁垒使得只有极小一部分潜在市场能够获得药物，严重阻碍了全球抗肥胖药物产业的成长。

市场趋势

随着製药公司努力克服单一促效剂疗法的临床局限性，提高耐受性和疗效的联合疗法的研发正在推动市场发展。製药公司正增加作用机制互补的药物的使用，例如将GLP-1类似物和Amylin类似物联合使用，旨在协同改善代谢结果并减重不利事件，最终目标是达到与减肥手术相当的减重效果。例如，2024年12月，诺和诺德宣布，其在研的固定剂量复方製剂Caglisema（卡格列肽和Semaglutide的组合药物）在REDEFINE 1试验中，经过68週的治疗，患者减重显着减轻了22.7%，远优于单药治疗。

同时，口服小分子製剂的出现正在重塑这一领域。这解决了注射用生物製药在规模化生产和用药依从性方面面临的挑战。与需要复杂低温运输物流的胜肽类注射剂不同，小分子药物可以更经济高效地生产，并以方便的每日片剂形式给药。这有望提高患者的用药可近性和依从性。这些製剂的研发正在快速开发平臺，为长期体重管理提供了一种非侵入性选择。 2024年11月，Viking Therapeutics公司报告称，接受最高剂量口服片剂VK2735治疗的患者，在短短28天的治疗后，平均体重减轻高达8.2%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球抗肥胖药物市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 作用机转（週边作用药物、中枢作用药物）
    • 药物类型（处方药、非处方药）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美抗肥胖药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲抗肥胖药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区抗肥胖药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲抗肥胖药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲抗肥胖药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球抗肥胖药物市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Alizyme PLC
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Currax Pharmaceuticals LLC
  • Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Pfizer Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24055

The Global Anti-Obesity Drugs Market is projected to expand from USD 3.21 Billion in 2025 to USD 8.04 Billion by 2031, registering a CAGR of 16.54%. This sector comprises pharmaceutical formulations aimed at facilitating weight reduction and maintenance through mechanisms such as appetite regulation, metabolic influence, or nutrient absorption. The market is experiencing robust growth fueled by the rising prevalence of chronic weight-related disorders and the increasing acceptance of pharmacotherapy as a treatment for comorbidities like type 2 diabetes. Highlighting the urgency for effective medical interventions, updated projections from the World Obesity Federation in 2025 estimate that the global number of adults living with obesity will rise to 1.13 billion by 2030.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.21 Billion
Market Size 2031USD 8.04 Billion
CAGR 2026-203116.54%
Fastest Growing SegmentPrescription Drugs
Largest MarketNorth America

However, a significant obstacle to broader market expansion is the high cost of novel therapeutics coupled with inadequate insurance reimbursement policies in many regions. These financial barriers frequently restrict patient access to long-term treatment regimens and may slow the adoption of advanced weight management solutions, particularly among lower-income populations.

Market Driver

The escalating global prevalence of obesity and overweight populations serves as the primary catalyst for market expansion, creating an urgent need for therapeutic interventions to alleviate public health burdens. This deepening metabolic crisis is driving demand for pharmaceutical solutions that address severe weight-related complications, shifting healthcare priorities toward medical management to prevent life-threatening conditions. According to the World Obesity Federation's 'World Obesity Atlas 2025', released in March 2025, overweight and obesity are responsible for approximately 1.6 million premature deaths annually from non-communicable diseases, underscoring the imperative for effective pharmacological treatments.

Concurrently, the sector has been transformed by the high clinical efficacy and commercial success of incretin-based therapies, which have established a new standard of care for regulating appetite and metabolic function. The substantial weight loss outcomes achieved by these biologics have validated pharmacotherapy for weight management, resulting in surging prescription volumes and robust revenue growth. This commercial viability is prompting competitors to accelerate the development of next-generation agonists. As noted in Novo Nordisk's 'Annual Report 2024' from February 2025, sales of its Obesity Care products rose by 57 percent to DKK 65.1 billion, while a December 2024 Fierce Pharma article reported that the company committed an additional DKK 2.9 billion to expand its quality control capabilities in Denmark.

Market Challenge

The rapid acceleration of the market is severely hindered by the high cost of novel anti-obesity medications, which often exceed thousands of dollars annually, combined with restrictive insurance policies. Health insurers and payers, wary of the financial strain associated with widespread utilization, have implemented stringent gatekeeping measures such as complex prior authorization requirements and strict body mass index thresholds. This reimbursement landscape creates a significant disconnect between clinical demand and commercial access, effectively excluding a large demographic of patients who are medically eligible but financially unable to afford out-of-pocket expenses, thereby limiting adoption primarily to affluent populations.

According to industry data cited by the Academy of Managed Care Pharmacy in 2025, only 31% of commercial plan members on average possessed coverage for anti-obesity medications, with payers citing high budget impacts as the primary barrier to broader reimbursement. This limited coverage forces the majority of potential patients to face prohibitive costs alone, directly reducing sales volume and preventing the market from reaching its full revenue potential. By restricting access to a fraction of the total addressable market, these financial barriers significantly curtail the growth trajectory of the global anti-obesity sector.

Market Trends

A dominant market force is the development of combination therapies designed to enhance tolerability and efficacy, as developers strive to surpass the clinical ceilings of mono-agonist treatments. Pharmaceutical companies are increasingly co-formulating agents with complementary mechanisms of action, such as GLP-1 analogues combined with amylin analogues, to synergistically improve metabolic outcomes and mitigate adverse events, aiming for weight loss results that rival bariatric surgery. For instance, Novo Nordisk announced in December 2024 that CagriSema, an investigational fixed-dose combination of cagrilintide and semaglutide, achieved a superior weight loss of 22.7% after 68 weeks in the REDEFINE 1 trial, significantly outperforming individual monotherapies.

Simultaneously, the sector is being reshaped by a transition toward oral small molecule formulations, which address the scalability and compliance limitations of injectable biologics. Unlike peptide-based injectables that require complex cold-chain logistics, small molecule drugs can be manufactured more cost-effectively and administered as convenient daily pills, potentially broadening patient access and adherence. This formulation evolution is rapidly advancing through clinical pipelines, offering a non-invasive alternative for long-term weight management. In November 2024, Viking Therapeutics reported that patients receiving the highest dose of its oral tablet formulation, VK2735, achieved a mean body weight reduction of up to 8.2% after just 28 days of treatment.

Key Market Players

  • Alizyme PLC
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Currax Pharmaceuticals LLC
  • Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Pfizer Inc

Report Scope

In this report, the Global Anti-Obesity Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Obesity Drugs Market, By Mechanism

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Anti-Obesity Drugs Market, By Drug Type

  • Prescription Drugs
  • OTC Drugs

Anti-Obesity Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Obesity Drugs Market.

Available Customizations:

Global Anti-Obesity Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Obesity Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Mechanism (Peripherally Acting Drugs, Centrally Acting Drugs)
    • 5.2.2. By Drug Type (Prescription Drugs, OTC Drugs)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Anti-Obesity Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Mechanism
    • 6.2.2. By Drug Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anti-Obesity Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Mechanism
        • 6.3.1.2.2. By Drug Type
    • 6.3.2. Canada Anti-Obesity Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Mechanism
        • 6.3.2.2.2. By Drug Type
    • 6.3.3. Mexico Anti-Obesity Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Mechanism
        • 6.3.3.2.2. By Drug Type

7. Europe Anti-Obesity Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Mechanism
    • 7.2.2. By Drug Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anti-Obesity Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Mechanism
        • 7.3.1.2.2. By Drug Type
    • 7.3.2. France Anti-Obesity Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Mechanism
        • 7.3.2.2.2. By Drug Type
    • 7.3.3. United Kingdom Anti-Obesity Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Mechanism
        • 7.3.3.2.2. By Drug Type
    • 7.3.4. Italy Anti-Obesity Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Mechanism
        • 7.3.4.2.2. By Drug Type
    • 7.3.5. Spain Anti-Obesity Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Mechanism
        • 7.3.5.2.2. By Drug Type

8. Asia Pacific Anti-Obesity Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Mechanism
    • 8.2.2. By Drug Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anti-Obesity Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Mechanism
        • 8.3.1.2.2. By Drug Type
    • 8.3.2. India Anti-Obesity Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Mechanism
        • 8.3.2.2.2. By Drug Type
    • 8.3.3. Japan Anti-Obesity Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Mechanism
        • 8.3.3.2.2. By Drug Type
    • 8.3.4. South Korea Anti-Obesity Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Mechanism
        • 8.3.4.2.2. By Drug Type
    • 8.3.5. Australia Anti-Obesity Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Mechanism
        • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Anti-Obesity Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Mechanism
    • 9.2.2. By Drug Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anti-Obesity Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Mechanism
        • 9.3.1.2.2. By Drug Type
    • 9.3.2. UAE Anti-Obesity Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Mechanism
        • 9.3.2.2.2. By Drug Type
    • 9.3.3. South Africa Anti-Obesity Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Mechanism
        • 9.3.3.2.2. By Drug Type

10. South America Anti-Obesity Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Mechanism
    • 10.2.2. By Drug Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anti-Obesity Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Mechanism
        • 10.3.1.2.2. By Drug Type
    • 10.3.2. Colombia Anti-Obesity Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Mechanism
        • 10.3.2.2.2. By Drug Type
    • 10.3.3. Argentina Anti-Obesity Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Mechanism
        • 10.3.3.2.2. By Drug Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anti-Obesity Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Alizyme PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bayer AG
  • 15.3. Bristol-Myers Squibb Co
  • 15.4. Currax Pharmaceuticals LLC
  • 15.5. Hoffmann-La Roche AG
  • 15.6. GlaxoSmithKline PLC
  • 15.7. Merck & Co. Inc.
  • 15.8. Norgine BV
  • 15.9. Novo Nordisk AS
  • 15.10. Pfizer Inc

16. Strategic Recommendations

17. About Us & Disclaimer